Public Release: 

Could less deadly therapies be a better way to keep cancer in check?

PLOS

While many cancer therapies initially can be very successful, tumors often return and spread when remaining cancer cells develop resistance to treatment. To combat this tendency, Frédéric Thomas of the French National Centre for Scientific Research proposes that cancer researchers take a lesson from our own immune system and explore "natural adaptive therapies." Such an approach would mimic the immune system's more restrained way of keeping cancer in check by gradually killing off cancerous cells. Ideally, these therapies would remove the evolutionary pressure that often leads to the spread of resistant tumors.

In Thomas' article, publishing 2nd October in the open access journal PLOS Biology, he and his colleagues reason that the body has evolved anti-cancer responses that direct and slow the evolution of life-threatening cancer cells by not killing off too many cells too quickly. Natural adaptive therapies would use a similar approach to keep tumor size stable, while slowing the evolution of resistance. This strategy may be especially useful to prolong lifespan and quality of life in patients after a cancer has metastasized.

The authors also explore the risk that cancer immunotherapies may force the immune system to rapidly kill malignant cells in a way that undermines the body's natural adaptive therapies, thus accelerating the evolution of immune resistance.

According to Thomas, further explorations into the mechanisms employed by the immune system to stabilize tumors could help researchers to identify new therapies to prevent tumor growth and metastasis.

###

In your coverage please use this URL to provide access to the freely available article in PLOS Biology: http://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.2007066

Citation: Thomas F, Donnadieu E, Charriere GM, Jacqueline C, Tasiemski A, Pujol P, et al. (2018) Is adaptive therapy natural? PLoS Biol 16(10): e2007066. https://doi.org/10.1371/journal.pbio.2007066

Funding: ANR EVOCAN. Received by FT. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.